Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8TOO

Crystal structure of Epstein-Barr virus gp42 in complex with antibody 4C12

Summary for 8TOO
Entry DOI10.2210/pdb8too/pdb
Descriptor4C12 light chain, 4C12 heavy chain, Glycoprotein 42, ... (4 entities in total)
Functional Keywordsviral protein, antibody, immune system
Biological sourceMus musculus (mouse)
More
Total number of polymer chains12
Total formula weight258816.99
Authors
Bu, W.,Kumar, A.,Board, N.,Kim, J.,Dowdell, K.,Zhang, S.,Lei, Y.,Hostal, A.,Krogmann, T.,Wang, Y.,Pittaluga, S.,Marcotrigiano, J.,Cohen, J.I. (deposition date: 2023-08-03, release date: 2024-03-27, Last modification date: 2024-11-13)
Primary citationBu, W.,Kumar, A.,Board, N.L.,Kim, J.,Dowdell, K.,Zhang, S.,Lei, Y.,Hostal, A.,Krogmann, T.,Wang, Y.,Pittaluga, S.,Marcotrigiano, J.,Cohen, J.I.
Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.
Immunity, 57:559-573.e6, 2024
Cited by
PubMed Abstract: Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with B cell lymphomas. EBV glycoprotein 42 (gp42) binds HLA class II and activates membrane fusion with B cells. We isolated gp42-specific monoclonal antibodies (mAbs), A10 and 4C12, which use distinct mechanisms to neutralize virus infection. mAb A10 was more potent than the only known neutralizing gp42 mAb, F-2-1, in neutralizing EBV infection and blocking binding to HLA class II. mAb 4C12 was similar to mAb A10 in inhibiting glycoprotein-mediated B cell fusion but did not block receptor binding, and it was less effective in neutralizing infection. Crystallographic structures of gH/gL/gp42/A10 and gp42/4C12 complexes revealed two distinct sites of vulnerability on gp42 for receptor binding and B cell fusion. Passive transfer of mAb A10 into humanized mice conferred nearly 100% protection from viremia and EBV lymphomas after EBV challenge. These findings identify vulnerable sites on EBV that may facilitate therapeutics and vaccines.
PubMed: 38479361
DOI: 10.1016/j.immuni.2024.02.008
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon